Reimbursement In Brief
This article was originally published in The Gray Sheet
Executive Summary
MedCAC pharmacogenomics meeting: The Medicare Evidence Development and Coverage Advisory Committee will meet Jan. 27, 2010, in Baltimore to review evidence on the impact of pharmacogenomic testing on health outcomes in cancer patients. Specifically, the panel will assess assays that might be used as a guide for certain drug treatments for breast cancer, colon cancer, chronic myelogenous leukemia or metastatic colorectal cancer. The upcoming meeting is the third in a series of MedCAC discussions held this year on evidence supporting genetic and genomic screening (1"The Gray Sheet" May 25, 2009)
You may also be interested in...
Research In Brief
ICD benefits in women: Meta-analysis of implantable cardioverter defibrillator studies published in the July issue of HeartRhythm shows that while women and men had the same overall mortality rates, women had significantly fewer ICD interventions on rapid, sustained ventricular tachycardia or fibrillation than men, "thus suggesting a smaller impact of sudden cardiac death on overall mortality in women with dilated cardiomyopathy." Researchers led by Pasquale Santangeli, Catholic University of the Sacred Heart in Rome, reviewed five studies that enrolled 7,229 patients with dilated cardiomyopathy, including Boston Scientific's MADIT II and the landmark Sudden Cardiac Death in Heart Failure trial
Research In Brief
ICD benefits in women: Meta-analysis of implantable cardioverter defibrillator studies published in the July issue of HeartRhythm shows that while women and men had the same overall mortality rates, women had significantly fewer ICD interventions on rapid, sustained ventricular tachycardia or fibrillation than men, "thus suggesting a smaller impact of sudden cardiac death on overall mortality in women with dilated cardiomyopathy." Researchers led by Pasquale Santangeli, Catholic University of the Sacred Heart in Rome, reviewed five studies that enrolled 7,229 patients with dilated cardiomyopathy, including Boston Scientific's MADIT II and the landmark Sudden Cardiac Death in Heart Failure trial
NICE To Seek Candidates For New-Tech Evaluation Program In First Half Of '10
Device and diagnostics companies should start thinking about products they would like to offer for evaluation under a new program in the U.K